Floatz logo

Cytosin-Arabinosid

Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent

Princess Maxima Center for Pediatric OncologyPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

24 Active assets in the Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent cohort.

Asset / SponsorPhaseRating
Blinatumomab
Amgen
Phase 3BBB
Fludarabine
National Cancer Institute (NCI)
Phase 2/3BB
Cyclophosphamide
Princess Maxima Center for Pediatric Oncology
Phase 2/3BB
Olverembatinib
First Affiliated Hospital of Zhejiang University
Phase 2B
PEGASPARGASE
First Affiliated Hospital of Zhejiang University
Phase 2B

View all 28 →

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →